Since January, the company has designated over 100 expert research and development scientists to contribute to projects for potential treatment solutions for COVID-19. The company has established additional collaborations with academia, biotech, and other pharmaceutical companies.

• Boehringer Ingelheim is committing over 11,000 hours in R&D to the Innovative Medicines Initiative.
• The company has also joined forces with the Bill & Melinda Gates Foundation COVID-19 Therapeutics Acceleration.
• Six of the company's antiviral compounds and 43 pharmacological tool compounds have been shared on the open innovation portal opnMe.com.

Additionally, Boehringer Ingelheim has made available $6.4 million in donations for emergency aid. The company is also offering paid leave to join external organizations to bring COVID-19 relief.

Committed to further contributions as needed, the company is working in broad strokes to tackle the virus, according to Cyrille Kuhn, PhD, executive director of research at Boehringer Ingelheim.